GeneFerm Biotechnology Co. Ltd. AI Stock Analysis
GeneFerm Biotechnology Co. Ltd. (1796) AI Stock Analysis
GeneFerm Biotechnology Co. Ltd.
(TPEx:1796)
GeneFerm earns a middling score. The financial foundation is the main positive: a low-leverage, equity-funded balance sheet, a return to revenue growth and profitability, and operating cash flow that comfortably exceeds reported net income. However, margins remain well below historical levels, return on equity is only 3.5%, and the multi-year record shows pronounced volatility in sales, profits and free cash flow. These fundamentals are offset by a weak price trend, with the stock trading below all major moving averages on negative MACD momentum, and by a demanding P/E of 66.9 that leaves little room for disappointment despite a reasonable 2.63% dividend yield.
GeneFerm Biotechnology Co. Ltd. (1796) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.16B
- Dividend Yield
- 2.50%
- Average Volume (3M)
- 19.36K
- Price to Earnings (P/E)
- 162.8
- Beta (1Y)
- 0.18
- Revenue Growth
- 7.05%
- EPS Growth
- ―
- Country
- TW
- Employees
- 288
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
GeneFerm Biotechnology Co. Ltd. Business Overview & Revenue Model
Company Description
GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line...
GeneFerm Biotechnology Co. Ltd. Financial Statement Overview
Summary
GeneFerm is a recovery story built on a conservative balance sheet. Revenue rebounded roughly 30% to NT$677 million and the company swung back to an operating profit of NT$46 million and net income of NT$29 million after prior-year losses, while operating cash flow jumped to NT$99 million and free cash flow turned positive at NT$76 million. The balance sheet is the strongest pillar: equity of NT$817 million funds about 64% of assets and debt-to-equity of 0.40 reflects multi-year deleveraging. Offsetting this, gross margin of 28.2% and net margin of 4.3% remain far below 2022-2023 peaks, return on equity is just 3.5%, and revenue, earnings and free cash flow have swung widely year to year, so the quality and durability of the recovery are still unproven.
Income Statement
52NeutralBalance Sheet
68PositiveCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 664.93M | 677.10M | 521.16M | 793.77M | 633.96M | 522.33M |
| Gross Profit | 167.71M | 190.80M | 96.75M | 286.35M | 222.16M | 192.65M |
| EBITDA | 97.08M | 115.40M | 56.34M | 231.09M | 163.34M | 124.51M |
| Net Income | 17.07M | 28.86M | -22.53M | 124.62M | 93.45M | 57.41M |
Balance Sheet | ||||||
| Total Assets | 1.27B | 1.28B | 1.15B | 1.18B | 1.19B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 281.97M | 280.26M | 122.45M | 120.15M | 100.69M | 539.61M |
| Total Debt | 312.78M | 324.23M | 246.19M | 127.44M | 219.16M | 464.70M |
| Total Liabilities | 482.31M | 464.00M | 358.31M | 282.54M | 358.86M | 569.22M |
| Stockholders Equity | 783.91M | 816.66M | 788.18M | 892.84M | 830.77M | 747.66M |
Cash Flow | ||||||
| Free Cash Flow | 78.15M | 75.89M | -14.61M | 118.91M | -155.98M | -33.37M |
| Operating Cash Flow | 110.78M | 99.31M | 8.09M | 190.31M | 122.43M | 112.23M |
| Investing Cash Flow | -32.31M | -22.59M | -22.83M | -70.62M | -280.33M | -145.25M |
| Financing Cash Flow | -39.65M | 81.06M | 16.38M | -99.87M | -281.79M | 224.81M |
GeneFerm Biotechnology Co. Ltd. Peers Comparison
Overall Rating
- TW:179652Neutral
TW:413348Neutral
TW:657842Neutral
TW:649633Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1796 | 52Neutral | TWD 1.14B | 162.76 | ― | 2.50% | 7.05% | ― |
| TW:4133 | 48Neutral | TWD 1.20B | 27.03 | ― | 0.56% | -4.19% | ― |
| TW:6578 | 42Neutral | TWD 1.21B | -51.66 | ― | 2.37% | 21.50% | -5.51% |
| TW:6496 | 33Underperform | TWD 1.13B | -5.88 | ― | ― | 11.64% | -10.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1796 | GeneFerm Biotechnology Co. Ltd. | 28.00 | -19.72 | -41.32% | |
| TW:4133 | Abnova Taiwan Corp. | 20.00 | -3.27 | -14.07% | |
| TW:4195 | Genomics BioSci & Tech. Co., Ltd. | 14.90 | -9.70 | -39.43% | |
| TW:6496 | Excelsior Biopharma Inc | 23.65 | -5.40 | -18.59% | |
| TW:6564 | Enimmune corporation | 14.90 | -5.67 | -27.55% | |
| TW:6578 | Dabomb Protein Biotech Corporation | 17.00 | -2.70 | -13.71% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026